H1 2024 Cytokine Landscape Review

Welcome to the H1 2024 Cytokine Landscape Review, your essential guide to the latest in cytokine therapeutics. In the first half of 2024, we’ve seen 164 new cytokine drugs and major approvals like WINREVAIR™ and Pyzchiva®. With 75 trials concluding by year’s end, and a surge in investment in novel targets, the clinical landscape is brimming with potential.

This review is packed with insights into new drug modalities, trial strategies, and investment trends, giving you the critical data needed to make intelligent cytokine development decisions.

Download

What does the Landscape Review cover?

Drug Landscape: An overview of top modalities, new assets and bispecific targets in H1 2024, plus a spotlight on cytokine-armored cell therapies.
Trial Landscape: Insights into trial initiation trends, autoimmune disease modalities, and combinations trials.
The Commercial Landscape: Analysis of deal values, development phases, company locations, and funding rounds.
Regulatory Announcements: Key regulatory milestones and IND/CTA approvals from H1 2024.
The Future of Cytokines: Predictions on target selection and future trends in the cytokine field, as well as a look at trials ending this year.

Download

Find out more

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

Each dataset features proprietary, hyper-relevant search and filtering tailored to specific modalities, in-depth data, plus additional market insight curated by our subject matter experts. Beacon is here to support you in making these decisions with confidence through our encompassing database solution.

With Beacon, you can make drug development decisions with confidence. This is why 23 out of the world’s top 25 drug developers trust us.

Discover more about Beacon